Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;72(2):e12782.
doi: 10.1111/jpi.12782. Epub 2021 Dec 30.

Safety of higher doses of melatonin in adults: A systematic review and meta-analysis

Zoe Menczel Schrire  1   2   3   4 , Craig L Phillips  4   5 , Julia L Chapman  1   2   3   4 , Shantel L Duffy  2   3   4   5 , Grace Wong  4 , Angela L D'Rozario  1   2   3   4 , Maria Comas  4 , Isabelle Raisin  6 , Bandana Saini  4   5 , Christopher J Gordon  4   5 , Andrew C McKinnon  1   2   3 , Sharon L Naismith  1   2   3 , Nathaniel S Marshall  4   5 , Ronald R Grunstein  4   5   7 , Camilla M Hoyos  1   2   3   4
Affiliations
Review

Safety of higher doses of melatonin in adults: A systematic review and meta-analysis

Zoe Menczel Schrire et al. J Pineal Res. 2022 Mar.

Abstract

Melatonin is commonly used for sleep and jetlag at low doses. However, there is less documentation on the safety of higher doses, which are being increasingly used for a wide variety of conditions, including more recently COVID-19 prevention and treatment. The aim of this review was to investigate the safety of higher doses of melatonin in adults. Medline, Scopus, Embase and PsycINFO databases from inception until December 2019 with convenience searches until October 2020. Randomised controlled trials investigating high-dose melatonin (≥10 mg) in human adults over 30 years of age were included. Two investigators independently abstracted articles using PRISMA guidelines. Risk of bias was assessed by a committee of three investigators. 79 studies were identified with a total of 3861 participants. Studies included a large range of medical conditions. The meta-analysis was pooled data using a random effects model. The outcomes examined were the number of adverse events (AEs), serious adverse events (SAEs) and withdrawals due to AEs. A total of 29 studies (37%) made no mention of the presence or absence of AEs. Overall, only four studies met the pre-specified low risk of bias criteria for meta-analysis. In that small subset, melatonin did not cause a detectable increase in SAEs (Rate Ratio = 0.88 [0.52, 1.50], p = .64) or withdrawals due to AEs (0.93 [0.24, 3.56], p = .92), but did appear to increase the risk of AEs such as drowsiness, headache and dizziness (1.40 [1.15, 1.69], p < .001). Overall, there has been limited AE reporting from high-dose melatonin studies. Based on this limited evidence, melatonin appears to have a good safety profile. Better safety reporting in future long-term trials is needed to confirm this as our confidence limits were very wide due to the paucity of suitable data.

Keywords: dementia; drug-related side effects and adverse reactions; melatonin; meta-analysis; preventative medicine; safety.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002-2012. Natl Health Stat Rep. 2015;79:1-16.
    1. Black LI, Clarke TC, Barnes PM, Stussman BJ, Nahin RL. Use of complementary health approaches among children aged 4-17 years in the United States: National Health Interview Survey, 2007-2012. Natl Health Stat Rep. 2015;78:1-19.
    1. Tordjman S, Chokron S, Delorme R, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15(3):434-443. doi:10.2174/1570159X14666161228122115
    1. Pro LPF, Con LM. Should melatonin be used as a sleeping aid for elderly people? Can J Hosp Pharm. 2019;72(4):327-329.
    1. Quera-Salva MA, Claustrat B. Melatonin: physiological and pharmacological aspects related to sleep: the interest of a prolonged-release formulation (Circadin(®)) in insomnia. Encephale. 2018;44(6):548-557. doi:10.1016/j.encep.2018.06.005

LinkOut - more resources